Acquisition of Ohr Pharmaceutical, Inc. - Consideration (Details) |
Jul. 12, 2019
USD ($)
$ / shares
shares
|
|---|---|
| Acquisition of Ohr Pharmaceutical, Inc. | |
| Number of shares of the combined company to be owned by Ohr security holders | shares | 2,829,248 |
| Fair value per share of Ohr common stock as of July 11, 2019 | $ / shares | $ 4.14 |
| Fair value of Ohr shares outstanding | $ 11,713,087 |
| Fair value of options assumed | 63,840 |
| Fair value of common stock and options issued | 11,776,927 |
| Transaction costs | 884,981 |
| Total cost of the Ohr acquisition | $ 12,661,908 |
| X | ||||||||||
- Definition Amount of shares assumed. No definition available.
|
| X | ||||||||||
- Definition Amount of shares acquired. No definition available.
|
| X | ||||||||||
- Definition The fair value per share of equity interest acquired. No definition available.
|
| X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|